Corvus Pharmaceuticals (CRVS) Accounts Payables (2015 - 2026)

Corvus Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 987.27% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (up 987.27% YoY), while the FY2025 annual figure was $2.5 million, down 3.52% from the prior year.
• Accounts Payables was $4.7 million for Q1 2026 at Corvus Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.7 million in Q1 2026 to a low of $432000.0 in Q1 2025.
• Historically, Accounts Payables has averaged $2.2 million across 5 years, with a median of $2.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables slumped 73.15% in 2025, then soared 987.27% in 2026.
• A 5-year view of Accounts Payables shows it stood at $2.0 million in 2022, then retreated by 22.82% to $1.5 million in 2023, then surged by 69.31% to $2.6 million in 2024, then retreated by 3.52% to $2.5 million in 2025, then jumped by 88.56% to $4.7 million in 2026.
• The last three Accounts Payables figures came in at $4.7 million (Q1 2026), $2.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.